Page 75 - Priority Review News Today

Pfizer (NYSE: PFE) announced today positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), demonstrating a statistically significant and clinically meaningful improvement in radiographic ...

The FDA has accepted for Priority Review the NDA for avacincaptad pegol (ACP) to treat geographic atrophy secondary to age-related macular degeneration.

-Total Revenues of $2.0 Billion in 2022, Including 23 Percent Annual Increase in Total Net Product Sales to $1.7 Billion--TUKYSA Granted FDA Accelerated Approval for Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer--ADCETRIS Received Pediatric Indication with FDA Approval for Children wit...

NEW YORK CITY (dpa-AFX) - Pfizer (PFE) Thursday reported positive results from the Phase 3 TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with

- PDUFA goal date is August 19, 2023 - ... | February 16, 2023

The FDA has accepted for Priority Review the sNDA for odevixibat for the treatment of Alagille syndrome.

If approved by the FDA, NARCAN Nasal Spray will be the first 4 mg naloxone nasal spray switched from prescription status to over-the-counter use ...

The FDA has accepted the NDA for avasopasem for radiotherapy-induced severe oral mucositis in patients with head and neck cancer.

/PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative...

The FDA has accepted for Priority Review the sNDA for linaclotide (Linzess) for the treatment of pediatric patients with functional constipation.